3 Life Science and Performance Chemicals Company, Active Ingredients Leader and Generic Drugs Maker Stocks With a Strong Future Roadmap: Atul, Divi’s Laboratories and Alembic Pharmaceuticals

Life science chemical, API and drug stocks give investors a way to track businesses that sit close to everyday demand in India. Atul, Divi’s Laboratories and Alembic Pharmaceuticals cover a chemicals company, an active ingredients leader and a generic drugs maker.

This list covers three life science chemical, API and drug stocks with complete current figures: Atul, Divi’s Laboratories and Alembic Pharmaceuticals. Every figure comes from the latest reported financials and the 3 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Life Science Chemical, API and Drug Stocks?

Life science chemical, API and drug stocks are listed companies that make life science and performance chemicals, produce active ingredients and custom synthesis products, and sell generic formulations in the United States and branded medicines in India. Their earnings depend on global orders and approvals.

Life Science Chemical, API and Drug Stocks at a Glance

On valuation, Atul and Alembic Pharmaceuticals trade at a P/E below the industry P/E, while Divi’s Laboratories trades above it, which reflects the growth the market already expects. Readers comparing life science chemical, API and drug stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in life science chemical, API and drug stocks can use the coming numbers to test whether growth is holding.

Why Do Life Science Chemical, API and Drug Stocks Have a Strong Roadmap in India?

Life science chemical, API and drug stocks have a strong roadmap in India because growing demand for specialty chemicals, global pharma outsourcing and rising generic use keep widening the market for these export linked companies.

• Chemicals. Crop and pharma users need specialty inputs.
• Active ingredients. Global drug firms outsource large volumes.
• Generics. US and Indian patients use more medicines.

Why Atul Features Among These Life Science Chemical, API and Drug Stocks

Among the life science chemical, API and drug stocks on this list, Atul is a Gujarat-based chemical company with life science chemicals for crop protection and pharmaceuticals, and performance and other chemicals that include aromatics, colours and polymers.

In the June 2026 quarter, revenue grew 25.1% year on year to Rs 1,881 crore, while net profit rose 91.8% to Rs 254 crore. Revenue rose from Rs 5,157 crore in FY22 to Rs 6,476 crore in FY26, a compound annual growth rate of 5.9%.

Net profit grew from Rs 507 crore in FY23 to Rs 689 crore in FY26, which works out to a compound annual growth rate of 10.8%. The company has a return on equity of 10.9%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 17,898 crore. The stock trades at a P/E of 22.1, below the industry P/E of 35.1.

Roadmap: The company supplies many industries from a single integrated site and has been adding capacity in higher-value chemicals. A broad product basket across agriculture, pharma and consumer uses spreads demand.

What to watch: Check capacity additions and demand in agrochemical and pharmaceutical intermediates.

Why Divi’s Laboratories Features Among These Life Science Chemical, API and Drug Stocks

Among the chemical and pharma shares on this list, Divi’s Laboratories is a Hyderabad-based maker of active pharmaceutical ingredients, intermediates and custom synthesis products, serving large global pharma companies from large-scale manufacturing sites.

The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0.

Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore.

Roadmap: The company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.

What to watch: Check the order flow in custom synthesis and the commissioning of new capacity.

Why Alembic Pharmaceuticals Features Among These Life Science Chemical, API and Drug Stocks

Among the three companies on this list, Alembic Pharmaceuticals is a Vadodara-based drug maker that sells generic formulations in the United States, branded medicines in India and active ingredients to other manufacturers.

Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%.

In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7.

Roadmap: The company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.

What to watch: Follow new approvals in the United States, the pace of complex generic launches and domestic growth.

Atul vs Divi’s Laboratories vs Alembic Pharmaceuticals on Key Financials

The table below sets the three life science chemical, API and drug stocks side by side on revenue, profit and margin, using reported figures.

Divi’s Laboratories posts the highest return on equity in this group at 15.3%. Divi’s Laboratories has the largest FY26 revenue at Rs 11,067 crore, and Alembic Pharmaceuticals shows the fastest revenue growth with a 8.4% compound annual rate. A useful habit with life science chemical, API and drug stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several aromatics, ingredient and formulation stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Life Science Chemical, API and Drug Stocks

Every theme carries risks that deserve a check before any decision. For these life science chemical, API and drug stocks, the main points are: Long-term chemical and pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Raw material and energy costs. Input prices can move margins in chemicals.
• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter life science chemical, API and drug stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Life Science Chemical, API and Drug Stocks

Life science chemical, API and drug stocks work best when investors track growth, valuation and return on equity side by side. Atul, Divi’s Laboratories and Alembic Pharmaceuticals each have a clear plan to grow. Based on the 3 November 2026 close, Atul trades at Rs 5,073, Divi’s Laboratories at Rs 10,064 and Alembic Pharmaceuticals at Rs 802.8. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these life science chemical, API and drug stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track life science chemical, API and drug stocks, set price alerts and get research-backed stock ideas.

What are life science chemical, API and drug stocks?

Ans. Life science chemical, API and drug stocks are listed companies that make life science and performance chemicals, produce active ingredients and custom synthesis products, and sell generic formulations in the United States and branded medicines in India. Their earnings depend on global orders and approvals. This list looks at three of them, Atul, Divi’s Laboratories and Alembic Pharmaceuticals, using reported FY22 to FY26 financials and the 3 November 2026 closing prices.

Which life science chemical, API and drug stocks are covered in this list?

Ans. This list covers Atul, Divi’s Laboratories and Alembic Pharmaceuticals. Based on the 3 November 2026 close, Atul traded at Rs 5,073, Divi’s Laboratories at Rs 10,064 and Alembic Pharmaceuticals at Rs 802.8. Their return on equity ranges from 10.9% to 15.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 8.4%.

Why do life science chemical, API and drug stocks have a strong future roadmap in India?

Ans. Life science chemical, API and drug stocks have a strong roadmap in India because growing demand for specialty chemicals, global pharma outsourcing and rising generic use keep widening the market for these export linked companies. The main drivers are as follows. Chemicals. Crop and pharma users need specialty inputs. Active ingredients. Global drug firms outsource large volumes. Generics. US and Indian patients use more medicines. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Atul performed financially?

Ans. Revenue rose from Rs 5,157 crore in FY22 to Rs 6,476 crore in FY26, a compound annual growth rate of 5.9%. Net profit grew from Rs 507 crore in FY23 to Rs 689 crore in FY26, which works out to a compound annual growth rate of 10.8%. In the June 2026 quarter, revenue grew 25.1% year on year to Rs 1,881 crore, while net profit rose 91.8% to Rs 254 crore. The company has a return on equity of 10.9%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 17,898 crore. The stock trades at a P/E of 22.1, below the industry P/E of 35.1. Looking ahead, the company supplies many industries from a single integrated site and has been adding capacity in higher-value chemicals. A broad product basket across agriculture, pharma and consumer uses spreads demand.

How has Divi’s Laboratories performed financially?

Ans. Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0. Looking ahead, the company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.

How has Alembic Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7. Looking ahead, the company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.

What risks should investors check before buying life science chemical, API and drug stocks?

Ans. Investors should check a few risks before buying life science chemical, API and drug stocks. Raw material and energy costs. Input prices can move margins in chemicals. Regulatory approvals. Plant inspections and approvals can affect supplies. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of life science chemical, API and drug stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 3 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.